|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismRHO gene transference |
|
|
|
Inactive Indication- |
Drug Highest PhaseIND Approval |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of ZVS101e Administered as a Single Monocular Subretinal Injection in Subjects With Bietti's Crystalline Dystrophy (BCD)
The purpose of this study was to evaluate the safety and efficacy of ZVS101e administered by subretinal injection in subjects with Bietti's crystalline dystrophy (BCD) and to select the optimal effective dose.
评价 ZVS101e 注射液在结晶样视网膜变性(BCD)受试者中单次单眼视网膜下注射给药的安全性和有效性的 I/II 期临床研究
[Translation] A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of a Single Monocular Subretinal Injection of ZVS101e Injection in Subjects with Crystalline Retinal Degeneration (BCD)
本研究的目的是评价ZVS101e注射液在结晶样视网膜变性(BCD)受试者中视网膜下注射给药的安全性和有效性,并选择最佳有效剂量。
[Translation] The purpose of this study is to evaluate the safety and efficacy of subretinal injection of ZVS101e injection in subjects with crystalline retinal degeneration (BCD), and to select the optimal effective dose.
100 Clinical Results associated with Chigenovo Co., Ltd.
0 Patents (Medical) associated with Chigenovo Co., Ltd.
100 Deals associated with Chigenovo Co., Ltd.
100 Translational Medicine associated with Chigenovo Co., Ltd.